Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
15 mars 2021 17h54 HE
|
Anchiano Therapeutics
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be...
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
15 déc. 2020 09h00 HE
|
Anchiano Therapeutics
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE...
Anchiano Appoints Stan Polovets as Chairman of the Board
26 mai 2020 08h00 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of...
Anchiano Therapeutics Reports First Quarter 2020 Financial Results
11 mai 2020 16h01 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new...
Anchiano Appoints Steve DiPalma as Chief Financial Officer
05 mai 2020 18h13 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr....
Anchiano to Hold Virtual Annual Meeting of Shareholders
17 avr. 2020 16h01 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders...
Anchiano Therapeutics Reports Year-End 2019 Financial Results
18 mars 2020 08h00 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...
Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders
17 janv. 2020 16h05 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s...
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
15 nov. 2019 08h30 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of...
Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
15 nov. 2019 08h30 HE
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...